Background: Impaired autoregulation may contribute to the pathogenesis of cerebral small vessel disease. Reliable protocols for measuring microvascular reactivity are required to test this hypothesis and for providing secondary endpoints in clinical trials.
Introduction
Cerebral small vessel disease (SVD) accounts for 20-25% of strokes and increases the risk of cognitive impairment, disability, and dementia. The pathogenesis is poorly understood but there is evidence of a role for increased vessel stiffness; 1, 2 it is hypothesized that affected arterioles do not vasodilate efficiently in response to demand for increased blood flow, leading to secondary ischemic damage. 3 Impaired cerebrovascular reactivity (CVR) has been reported in Alzheimer's dementia 4 and cerebral amyloid angiopathy. 5 As a result, there is growing interest in endothelial dysfunction as a therapeutic target for treating SVD and clinical trials of licensed drugs with relevant modes of action (e.g. Cilostazol and isosorbide mononitrate; https://clinicaltrials.gov/ct2/ show/NCT02481323) and antihypertensive drugs have recently commenced at our center and elsewhere.
Clinically feasible and reliable non-invasive methods for assessing microvessel reactivity would provide mechanistic insight and secondary endpoints in trials of drugs to prevent and reverse SVD. Transcranial Doppler ultrasound combined with a hypercapnic or pharmacologic challenge is well-established, and has been used to show reduced CVR in age-matched subjects with white matter hyperintensities (WMH) and similar vascular risk factors, 6 but only provides information on blood flow in a chosen large artery. In contrast, MRI permits CVR measurement throughout the brain using blood oxygenation level dependent (BOLD) imaging or arterial spin labelling (ASL) in response to a respiratory challenge. However, although CVR MRI has been widely used to study large artery diseases such as Moyamoya and carotid stenosis, 7, 8 the technique has infrequently been applied in the study of SVD. [9] [10] [11] [12] [13] [14] Although the aims, methods, and findings of these studies were varied, Uh et al. 14 reported a reduction in CVR both in WMH compared with normal-appearing WM (NAWM) and in the NAWM of subjects with greater WMH burden. This suggests a potentially valuable role for CVR measurement as a secondary endpoint in clinical trials of drugs for SVD prevention and reversal.
The aim of our work was to develop and pilot a robust, reliable, and well-tolerated protocol for reproducible measurement of CVR in patients presenting with minor ischemic stroke, with emphasis on measurements in subcortical regions of the brain. The minor stroke population allows both assessment of CVR in relation to stroke etiology (SVD versus large artery disease) and CVR in relation to specific SVD radiological features, which while more common in SVD stroke are prevalent in stroke patients regardless of stroke etiology. 15, 16 We tested two different hypercapnia paradigms with BOLD MRI, with repeat scanning to measure reproducibility, and recorded tolerability and symptoms associated with the procedures. In addition, we developed an image analysis protocol for measuring CVR in multiple grey matter (GM) and white matter (WM) brain areas relevant to SVD, including subcortical GM, deep WM, and periventricular regions, deriving CVR and CVR delay values for both healthy volunteers and patients.
Methods

Participants
We recruited healthy volunteers, who were asked to attend two CVR scanning sessions, and patients with a history of minor stroke, who were invited to a single scanning session. The study was conducted following Research Ethics Committee approvals (ref. 14/HV/ 0001 and 14/EM/1126) and according to the principles expressed in the Declaration of Helsinki. All subjects gave written informed consent.
Healthy volunteers were recruited from the surrounding area, excluding any potential participants having cardiovascular or respiratory illness, hypertension, migraine, anxiety disorders, and panic attacks; we also excluded those with a known family history of intracranial aneurysm, subarachnoid hemorrhage, arteriovenous malformation as well as those with contraindications to MRI.
Patients were recruited from the in-and out-patient stroke service as described previously. 17, 18 We recruited patients presenting with a new clinical diagnosis of minor ischemic stroke, i.e. that was non-disabling, and also from our register of patients with a clinical diagnosis of minor non-disabling ischemic stroke in the past five years. ''Non-disabling'' was defined as not requiring assistance in activities of daily living. We included those with diabetes, hypertension, and other vascular risk factors as long as these were well controlled. We excluded patients with unstable hypertension, unstable diabetes, other neurological disorders, significant cardiac or respiratory illness or other life threatening medical conditions. We also excluded patients unable to give consent, with contraindications to MRI, and who had hemorrhagic stroke (but not hemorrhagic transformation of an infarct).
Participants were administered CO 2 in medical air at a concentration of 6% via a disposable anesthetic face mask (Intersurgical, Wokingham, UK) for a test period prior to entering the scanner in order to familiarize them with the respiratory challenge and related equipment, and to monitor them for anxiety and other symptoms. Anecdotally, it has been reported that a 4% CO 2 gas mixture is noticeably better tolerated compared with 6% CO 2 , though a smaller vasodilatory effect is expected. Therefore, we used simple randomization to allocate the first 10 patients to either 4% CO 2 or 6% CO 2 to assess the impact on procedure tolerability and aid in the planning of future studies; patients but not researchers were blinded to CO 2 concentration.
Magnetic resonance imaging
During CVR MRI, subjects wore a unidirectional breathing circuit (Figure 1 ) designed by the University International Journal of Stroke, 13 (2) of Aberdeen and Intersurgical (Wokingham, UK; product code: 2013018) that enabled administration of air or a gas mixture containing 4 or 6% carbon dioxide; the circuit was open to room air via a length of anesthetic breathing circuit (with a volume greater than tidal volume (350 ml)) that served as a gas reservoir and ensured participant safety when the cylinder gas flow rate was insufficient or turned off. To ensure that accurate concentrations of CO 2 were administered, two cylinders of certified, medical grade gas mixtures were used, containing 6% CO 2 , 21% O 2 , 73% N 2 , and 4% CO 2 , 21% O 2 , 75% N 2 , respectively (BOC Special Products, UK). The CO 2 gas mixture was administered to volunteers using both a ''1-min'' (four 1-min blocks of air alternated with three 1-min blocks of CO 2 ) 20 and a ''3-min'' (three 2-min blocks of air interleaved with two 3-min blocks of CO 2 ) 21 paradigm; as the results showed improved reproducibility with the latter, the 3-min paradigm alone was used for patient CVR scans. We measured vital signs (peripheral oxygen saturation, blood pressure, heart rate, end-tidal CO 2 (ETCO 2 ), and respiratory rate) using a CD-3A CO 2 sensor (AEI Technologies, Pittsburgh, USA) and MR patient monitors (Millennia 3155A and Magnitude 3150 MRI; Invivo, Best, The Netherlands). Gas cylinders and CO 2 sensors were positioned in the MR control room; tubes and sample lines entered the scanner room via a waveguide.
Magnetic resonance imaging was acquired with a 1. Participants were asked to rate the tolerability of the CVR procedure on a four-point scale (''intolerable,'' ''not very tolerable,'' ''tolerable,'' or ''very tolerable'') and healthy volunteers were asked which of the two paradigms was more tolerable. 
Image processing and analysis
End-tidal CO 2 . ETCO 2 values were obtained using the Millenia monitor with 1-s temporal resolution and stored digitally. For patients and a subset of the volunteers, CO 2 waveforms generated by the CD-3A sensor were recorded digitally with a sampling rate of 20.s À1 ; these were converted to ETCO 2 profiles using in-house Matlab code for identifying peaks in CO 2 concentration corresponding to end-tidal values (MathWorks, Inc., MA, USA), which were temporally aligned with the Millenia ETCO 2 profile. The CD-3A sensor was calibrated prior to each scan using room air and the certified gas mixtures, and readings from this device were used for determining CVR in patients; since most of the volunteers were measured using the Millenia monitor, ETCO 2 readings were calibrated against the CD-3A device in a subset of volunteers so that data for patients and volunteers could be compared.
CVR.
A range of parameters and quantification methods have been proposed for CVR measurement, including linear regression with 22 and without 20 a tissue-dependent delay, parameterization of the ETCO 2 -BOLD response curve, 23 frequency-domain analysis, 24 and fitting the signal response using a nonlinear model. 25 We chose to use linear regression with a variable CVR delay, since this method is relatively computationally efficient and there is good evidence for a tissue-dependent delay in the BOLD response to CO 2 . 22 The BOLD signal was regressed with an intercept against ETCO 2 and scan number (to account for linear signal drift). The CVR (units %/mmHg) is the regression coefficient corresponding to the ETCO 2 regressor, with the latter shifted by the delay that minimizes the residual sum of squares, and is expressed as a percentage of the mean signal during the first 45 s of the paradigm. CVR and CVR delay were calculated in a voxel-wise manner to generate parameter maps using the mean signal for each ROI. CVR delay values were adjusted by þ4 s to account for the time delay between exhalation and detection of CO 2 concentration changes.
Image pre-processing. MR images were converted from DICOM to NIFTI format using SPM8 (Wellcome Department of Imaging Neuroscience, London, UK); BOLD dummy scans recorded prior to the start of the paradigm were discarded and the remaining volumes were spatially aligned to the mean volume using the two-pass procedure in SPM8. T1W images were coregistered to the T2W images using rigid-body registration and the transformation between the T2W and mean BOLD image spaces was determined (FSL FLIRT 26 ).
Regions of interest. The contrast-to-noise ratio of the BOLD signal for individual voxels is generally small, resulting in somewhat noisy parameter maps, particularly in the WM. 24 Many studies have employed automatically generated tissue masks as regions of interest (ROIs) to increase the contrast-to-noise ratio and improve the model fitting, though such an approach does not provide regional information and assumes a global CVR delay. We therefore selected an intermediate approach, using ROIs to reduce the influence of noise 22 while retaining region-and tissue-specific information. Sixteen ROIs were chosen to sample WM and subcortical GM brain areas affected by SVD in addition to two cortical GM ROIs (Figure 2) . First, an axial slice intersecting the basal ganglia was chosen and ROIs covering the caudate heads, thalamus, and putamen were drawn. A second slice superior to the basal ganglia showing the lateral ventricles was chosen for WM (periventricular, frontal and posterior) and cortical GM (frontal and parietal lobe) ROIs. Finally, a slice superior to the lateral ventricles was selected and ROIs covering the centrum semiovale were drawn. For each slice, the ROIs were extended to cover the same regions or structures on a neighboring slice to increase the signal-to-noise ratio (for frontal and posterior WM ROIs, three neighboring slices were used). For patients, stroke lesions (as identified on the FLAIR image) were excluded from the ROIs. Finally, the ROIs were overlaid on the co-registered CVR maps; voxels covering midline hyperintensities on the CVR maps corresponding to blooming around the large veins and venous sinuses were excluded to reduce the influence of large vessels.
Statistical analysis
Descriptive statistics in the text are presented as mean AE standard deviation. Differences within and between the participant groups were tested in Matlab using the t-test, assuming unequal variance for unpaired data and with p < 0.05 (two-sided) as the significance threshold. Reproducibility was measured using variance component analysis in Matlab (anovan function) and illustrated using Bland-Altman plots. 27 The standard deviations resulting from this procedure are presented as coefficients of variation (CVs), i.e. normalized to the mean (averaged first over both visits and then over subjects).
but experienced claustrophobia shortly after entering the scanner and a second experienced anxiety during the pre-scan CO 2 test run); 11 of the 13 volunteers scanned agreed to be scanned on a second occasion (one had left the area, a second was excluded due to anxiety during the first visit); one of the repeat scans was halted due to sustained tachycardia that was likely caused by anxiety exacerbated by head cold symptoms (the subject had rated the first scan ''very tolerable''). Two scans were interrupted due to scanner failure; at two of the visits, the start time was not recorded, providing CVR but not CVR delay values. Most of the International Journal of Stroke, 13(2)
CVR scans (11/15 for visit 1, 9/12 for visit 2) were rated as either ''tolerable'' or ''very tolerable'' ( Figure 3 ). Volunteers had a range of previously described hypercapnia-related symptoms: respiratory symptoms (variously reported as shortness of breath, breathing resistance etc.; n ¼ 12 of 24 CVR scanning sessions initiated), anxiety (n ¼ 2), and temporary nausea, paraesthesia, confusion and blurred vision (n ¼ 1). Three participants had transient tachycardia apparent from physiological monitoring data. No symptoms were reported following 10 of the scans. One subject reported the 3-min paradigm as more tolerable, while two subjects preferred the 1-min paradigm and one subject chose a different paradigm at either visit; the remainder had no preference.
Among the 15 patients (mean age 66.4 AE 8.1, range 53-77 years; 20 % female), 14/15 completed CVR scanning, compared with 13/15 for the volunteers (one subject tolerated the hypercapnic challenge outside the scanner but was unable to tolerate MRI due to claustrophobia), all of whom rated the procedure as ''tolerable'' or ''very tolerable'' (Figure 3 ). Five patients reported no hypercapnia symptoms, while others reported respiratory symptoms (n ¼ 9), anxiety (n ¼ 1) and paraesthesia (n ¼ 1). Tolerability was similar among the 10 patients randomized to different CO 2 concentrations: patients administered 4% CO 2 rated the scans as very tolerable (n ¼ 2), tolerable (n ¼ 2) or intolerable (n ¼ 1; experienced claustrophobia as noted above), while those administered 6% CO 2 rated the scans as either very tolerable (n ¼ 4) or tolerable (n ¼ 1). Since similar CVR values were observed (Figure 4 (e) and (f)) with greater changes in ETCO 2 for 6% versus 4% CO 2 administration (12.8 AE 3.7 vs. 8.0 AE 1.0 mmHg, p < 0.01), the higher CO 2 concentration was used for subsequent patient scans.
Patients had a range of radiological SVD features including lacunes (60%), cerebral microbleeds (6.7%), enlarged perivascular spaces (PVS; basal ganglia PVS scores: 1 (40%), 2 (40%), 3 (20%); centrum semiovale PVS scores: 0 (0%), 1 (33.3%), 2 (6.7%), 3 (46.7%), 4 (13.3%)), and WMH (perventricular Fazekas scores: 0 (6.7%), 1 (60%), 2 (33.3%); deep WM Fazekas scores: 0 (13.3%), 1 (66.7%), 2 (20%)).
Comparison of paradigms and reproducibility in healthy volunteers
CVR and CVR delay measurements for each ROI are shown in Table 1 and Figure 4 (a) and (b). Average CVR was significantly greater for the 3-min versus the 1-min paradigm for all ROIs (0.041-0.313 vs. 0.021-0.251%/ mmHg respectively, p < 0.05); the average CVR delay was similar in most GM ROIs, but was longer for the 3-min paradigm in WM ROIs. Inter-visit coefficients of variation (CV; Table 2 ) were lower for the 3-min paradigm in most ROIs (7.9-15.4% vs. 11.7-70.2% respectively for CVR in GM). Large or negative variance estimates were found in some ROIs for the 1-min paradigm; inspection of the Bland-Altman plots (Supplementary Figures 1 to 4) and individual model fits showed these data to be affected by outliers caused by the periodicity of the 1-min paradigm; as illustrated in Supplementary Figure 5 , the algorithm fits some noisy data by reversing the sign of the fitted CVR while increasing the CVR delay by 60 s. This effect was not seen for the 3-min paradigm due to the lower frequency of the stimulus. Table 1 and Figure 4 CVR delay values for healthy volunteers and patients, obtained using the 3-min gas paradigm. (e-f) compare mean (e) CVR and (f) CVR delay for patients scanned using 4% (n ¼ 4) and 6% (n ¼ 10) CO 2 gas mixtures. ''*'' indicates a significant difference (p < 0.05) between paradigms, between patients and volunteers, or between CO 2 concentrations; error bars indicate the standard deviation after averaging over visits (healthy volunteers only).
Regional CVR in healthy volunteers and patients
Source: Thrippleton et al. 19 
Discussion
Several cerebrovascular vasodilatory stimuli and paradigms have been presented in the literature but rarely tested in our patient population. Our first aim was therefore to select a suitable stimulus for studies of cerebral SVD and minor stroke. A range of methods have been proposed, including simple respiratory challenges such as breath-holding and hyperventilation, pharmacologic stimuli such as acetazolamide, inspired gas challenges, and automated systems for targeting precise changes in end-tidal gas concentration. We selected a hypercapnic challenge because CO 2 is endogenous, simple to administer and measure using widely available equipment, and safe to inhale at low concentrations. A fixed-inspired CO 2 challenge was chosen as a compromise between experimental precision and ease of implementation for use in multicenter clinical studies: unlike an acetazolamide injection, a CO 2 stimulus is easily administered and quickly reversed; hyperventilation and breath-hold challenges require less equipment but rely on a higher degree of participant cooperation, and with breath holding it is difficult to monitor the participant's physiological parameters non-invasively. The benefits and drawbacks of different CVR challenges, 25, 26 and other practical aspects of CVR measurement in clinical research, 28 have been discussed in detail elsewhere. We chose to use a 6% CO 2 concentration in medical air since we measured similar CVR values and tolerability with greater ETCO 2 and signal changes with this gas mixture in a randomized comparison with 4% CO 2 . Carbogen (CO 2 and O 2 with no nitrogen) gas mixtures have also been used for measuring CVR but the effects on the BOLD signal via changes in CBF and other mechanisms are more complex. 29 The experiments performed here could also be performed using a computerized system for prospective targeting of ETCO 2 values, subject to sufficient patient cooperation, availability of specialized equipment and provided a calibration step is performed before CVR scanning; such an approach should result in a more reproducible stimulus with better correspondence between ETCO 2 and arterial PaCO 2 . 30 Comparing two previously published hypercapnia paradigms, we found the paradigm based on 3-min CO 2 spells to be more reliable than a 1-min paradigm for measuring CVR and the CVR delay. This is partly because more signal is collected during the 3-min paradigm (12 min vs. 7 min total duration). Another factor is the longer repetition period of the 3-min paradigm, which reduces the likelihood of selecting the ''wrong'' minima as illustrated in Supplementary Figure 5 . Such errors were observed in a small number of cases only due to the use of pre-scan ETCO 2 data, which negates the periodicity of the paradigm; such errors could be further suppressed by further constraining the permitted delay values, but this would potentially bias International Journal of Stroke, 13 (2) the results, particularly in regions, voxels, or patients with slow CVR response (the group of greatest interest) and appropriate arbitrary limits would be difficult to determine a-priori without further knowledge of human cerebrovascular biology. We also found that CVR and the CVR delay were on average greater for the 3-min paradigm, with the difference more pronounced in WM ROIs. This observation suggests that the linear regression model is an incomplete description of the BOLD response to changes in ETCO 2 . Improved fitting will likely result from convolving the ETCO 2 regressor with an impulse response function 21 or by permitting multiple (e.g. fast and slow) components to the response in any given tissue. However, the ideal approach is yet to be determined and the inclusion of additional fitting parameters would increase the computational burden and likely reduce the precision of other parameters. Further investigation is required to determine the optimal approach and care should be taken when comparing CVR values between studies. In general, data were more reproducible for GM than WM ROIs, which is expected due to the greater CBF in GM. The tolerability was similar for the two paradigms tested. Healthy volunteers had a similar rate of hypercapnia-related symptoms to patients but, on average, found the CVR procedure less tolerable compared with patients; this may be due to the administration of two CVR paradigms per session in volunteers, or due to healthy volunteers being less accustomed than patients to medical procedures. Encouragingly, all patients who underwent CVR scanning described the experience as either ''tolerable'' or ''very tolerable.'' In an analysis of 434 CVR scans across multiple patient groups, Spano et al. 30 also reported a high success rate for examinations using a prospective ETCO 2 targeting approach, with CVR maps generated for 83.9% of scans.
There are limited data on the reproducibility of BOLD CVR in the literature. Goode et al., 32 using 10% CO 2 (9 min paradigm duration at 1.5T) reported coefficients of variation for CVR of around 25% in whole-brain GM and WM regions, 32 comparable to our findings. Kassner et al. 33 reported higher reproducibility (6.8% and 9.9% in GM and WM, respectively, at 1.5T) using a paradigm of around 12-min duration, 33 attributing this to more precise control of the ETCO 2 stimulus through use of a rebreathing circuit; the use of whole-brain ROIs and a constant CVR delay would also likely influence their findings.
The voxel-wise BOLD signal response to hypercapnia typically has low contrast-to-noise ratio, particularly in the WM, resulting in noisy parameter maps. As a result, several previous studies have used wholebrain tissue masks, but this precludes region-specific information needed for studies of SVD, which primarily affects periventricular WM, deep WM, and subcortical GM. We therefore selected an intermediate approach, averaging signal over ROIs to reduce parameter uncertainty while retaining region-specific information. This approach also permits manual exclusion of the large draining veins and sinuses, which have a significant influence on the signal in surrounding voxels due to the ''blooming'' effect. Despite this approach, reproducibility was lower in ROIs with low CVR; use of higher field MRI (e.g. 3T) should in principle permit increased reproducibility in these regions.
In common with previous volunteer studies, we found CVR to be greater in GM than in WM. Few if any studies have specifically measured subcortical GM CVR, which we found to be comparable to that in cortical GM. CVR values measured using the 1-min CO 2 challenge in GM and WM had similar magnitude to those reported by Thomas et al. 22 using the same paradigm. Within the WM, CVR was greater in periventricular ROIs than in the deep WM areas, which may be due to inclusion in the ROI of the draining veins surrounding the lateral ventricles (it being very difficult to ensure that no draining veins have been included). Also, in agreement with Thomas et al., we report a delay of approximately 20 s between the BOLD responses in GM and WM; this difference was greater still using the 3-min paradigm. Sam et al. 13 also observed differences between GM and WM in addition to reporting data for WMH, which were found to have reduced CVR and increased delay compared with normal-appearing WM. It is noted that the speed and magnitude of the WM response could be influenced by a steal effect by the faster-responding GM in addition to differences in intrinsic tissue properties such as cerebral blood volume and vasodilatory function. 34 BOLD CVR was on average greater in healthy volunteers than in patients for most ROIs. Since the primary purpose of this work was to develop and assess protocols, the groups were not matched for age or vascular risk factors. However, the difference is consistent with the expected reduction in vasoreactivity both with ageing 35, 36 (patients were older than the healthy volunteers) and cerebrovascular disease. 6, 14 More surprisingly, the CVR delay was shorter for patients in most ROIs. Thomas et al. also reported a longer CVR delay in young versus older participants, though neither group comprised patients.
Other aspects of the BOLD CVR examination protocol, not addressed in this work, should also be considered for CVR studies in SVD. While a field strength of 1.5 T, as used in this work, has the benefit of wide availability in clinical settings, 3T scanning would likely increase reproducibility as a result of higher signal-and contrast-to-noise ratio for BOLD MRI; adverse susceptibility effects including blooming artefacts around the large veins are also greater at 3 T, but this can be mitigated by increasing bandwidth and reducing voxel size, which will also reduce partial volume effects on CVR values, particularly in small structures and lesions. We also did not address the optimization of MR acquisition parameters, using, as in most CVR studies, ''standard'' BOLD fMRI values for the echo time and repetition time. The choice of echo time affects the signal-to-noise ratio, sensitivity to deoxyhaemoglobin, and other aspects of the acquisition protocol. Ravi et al. 37 proposed the use of a shorter echo time to suppress negative CVR values that were attributed by the authors to displacement of CSF by dilated vessels. Finally, the increasing availability of simultaneous multislice and other parallel imaging techniques on commercial MR scanners will facilitate higher spatial and/or temporal resolution in future studies. 38 The ''HARNESS'' (Harmonising Brain Imaging Methods for Vascular Contributions to Neurodegeneration) collaboration, currently in progress, and ongoing discussions within the wider CVR community, should result in further recommendations and guidance relevant to the conduct of CVR experiments in SVD research.
In conclusion, the protocol described herein will permit further investigation of the relationship between cerebral SVD burden and subcortical CVR in crosssectional studies of patients presenting with minor ischemic stroke, cognitive impairment, and CADASIL (INVESTIGATE-SVDs: ISRCTN1051422). Since the progression of WM changes visible by structural MRI is typically slow, 39 this protocol will also be used to provide intermediary end-points in clinical trials of drugs to prevent and reverse SVD (LACI-1: ISRCTN12580546, TREAT-SVDs: NCT03082014).
